Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody

被引:31
作者
Bloechl, S
Beck, R
Seidl, C
Morgenstern, A
Schwaiger, M
Senekowitsch-Schmidtke, R
机构
[1] Tech Univ Munich, Nukl Med Klin, Dept Nucl Med, D-81675 Munich, Germany
[2] Commiss European Communities, Joint Res Ctr, Inst Transuranium Elements, D-7500 Karlsruhe, Germany
关键词
SOLID TUMORS; NUDE-MICE; ALPHA; THERAPY; BI-213; TOXICITY; PROSTATE; ADHESION; EMITTERS;
D O I
10.1158/1078-0432.CCR-1004-0017
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Locoregional radioimmunotherapy of i.p. tumor cell dissemination of diffuse-type gastric cancer using the a-emitter 213 Bi displayed good therapeutic results after a single application depending on the time interval between tumor cell inoculation and injection of the 213 Bi-immunoconjugate. The aim of the present study was to compare single versus double i.p. injection of a tumor-specific antibody (d9MAb) conjugated with low activities of Bi-213 in terms of therapeutic efficacy and,toxicity. Experimental Design: Nude mice were inoculated i.p. with 1 X 10(7) human gastric cancer cells (HSC45-M2) expressing tumor-specific mutant d9-E-cadherin (d9-E-cad). After tumor cell inoculation, the mice were injected i.p. with a single injection at day 1 or 8, or double injections at days 1 and 8 or days 8 and 15 with 0.37, 0.74, or 1.48 MBq(213)Bi-d9MAb. Therapeutic efficacy was determined by median survival, and toxicity was evaluated by leukocyte and platelet counts. The development of i.p. carcinomatosis was monitored by carcinoembryonic antigen concentrations in the serum of the mice. Results: The median survival of treated animals increased, depending on the time interval (days) between tumor cell inoculation and therapy, and the injected activity, from 22 days of untreated mice to 48 days (0.37 MBq,1 day), 84 days (0.37 MBq, 1 and 8 days), 37 days (0.37 MBq, 8 days), 46 days (0.37 MBq, 8 and 15 days), 42 days (0.74 MBq 8 days), 78 days (0.74 MBq, 8 and 15 days), and 44 days (1.48 MBq, 8 days). The injected activities did not reduce leukocyte and platelet counts. Carcinoembryonic antigen, which was not detectable in the serum of tumor-free mice, increased after tumor cell inoculation and tumor proliferation and decreased after each therapeutic application of Bi-213-d9MAb. Conclusions: Double application of only 0.37 MBq of Bi-213-d9MAb at days 1 and 8 after tumor cell inoculation significantly prolonged median survival in nude mice suffering from i.p. tumor cell dissemination compared with a single injection. Even in an advanced stage of the disease, double injection of 0.74 MBq at days 8 and 15 was superior to a single injection of 1.48 MBq at day 8 without any sign of toxicity.
引用
收藏
页码:7070S / 7074S
页数:5
相关论文
共 27 条
  • [1] Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules
    Adams, GP
    Shaller, CC
    Chappell, LL
    Wu, C
    Horak, EM
    Simmons, HH
    Litwin, S
    Marks, JD
    Weiner, LM
    Brechbiel, MW
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2000, 27 (04) : 339 - 346
  • [2] In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers
    Allen, BJ
    Rizvi, S
    Li, Y
    Tian, Z
    Ranson, M
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 39 (1-2) : 139 - 146
  • [3] Andersson H, 2000, ANTICANCER RES, V20, P459
  • [4] Apostolidis C., 2001, NUCL NEWS, V44, P29
  • [5] Functional allelic loss detected at the protein level in archival human tumours using allele-specific E-cadherin monoclonal antibodies
    Becker, KF
    Kremmer, E
    Eulitz, M
    Schulz, S
    Mages, J
    Handschuh, G
    Wheelock, MJ
    Cleton-Jansen, AM
    Höfler, H
    Becker, I
    [J]. JOURNAL OF PATHOLOGY, 2002, 197 (05) : 567 - 574
  • [6] Behr TM, 1999, CANCER RES, V59, P2635
  • [7] Borchardt PE, 2003, CANCER RES, V63, P5084
  • [8] Intraperitoneal radioimmunotherapy with human monoclonal IGM in nude mice with peritoneal carcinomatosis
    Borchardt, PE
    Quadri, SM
    Freedman, RS
    Vriesendorp, HM
    [J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2000, 15 (01) : 53 - 64
  • [9] AN EFFECTIVE CHELATING AGENT FOR LABELING OF MONOCLONAL-ANTIBODY WITH BI-212 FOR ALPHA-PARTICLE MEDIATED RADIOIMMUNOTHERAPY
    BRECHBIEL, MW
    PIPPIN, CG
    MCMURRY, TJ
    MILENIC, D
    ROSELLI, M
    COLCHER, D
    GANSOW, OA
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-CHEMICAL COMMUNICATIONS, 1991, (17) : 1169 - 1170
  • [10] Rationales, evidence, and design considerations for fractionated radioimmunotherapy
    DeNardo, GL
    Schlom, J
    Buchsbaum, DJ
    Meredith, RF
    O'Donoghue, JA
    Sgouros, G
    Humm, JL
    DeNardo, SJ
    [J]. CANCER, 2002, 94 (04) : 1332 - 1348